Kite CEO Christi Shaw to de­part Gilead CAR-T unit

Christi Shaw will leave her post as CEO of Gilead’s Kite Phar­ma at the end of this quar­ter, Gilead said Fri­day morn­ing.

Shaw led the CAR-T cell ther­a­py com­pa­ny since 2019, more than a year af­ter Gilead swooped in to buy the biotech for about $12 bil­lion.

She over­saw a cell ther­a­py mak­er that de­liv­ered its CAR-T treat­ments, Yescar­ta and Tecar­tus, to about 13,000 pa­tients in more than 20 coun­tries fol­low­ing the for­mer’s first ap­proval in 2017, Gilead said. The bio­phar­ma is one of a few to have so far re­ceived FDA clear­ance for au­tol­o­gous cell ther­a­pies, as the in­dus­try tries ex­pand­ing the ther­a­peu­tic tools’ scope from blood can­cers to oth­er ar­eas of on­col­o­gy.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER